roniciclib + cisplatin + etoposide

This is a **combination therapy** comprising **roniciclib, cisplatin, and etoposide**. - **Roniciclib** is an investigational, orally available, potent inhibitor of multiple cyclin-dependent kinases (CDKs), including CDK1, CDK2, CDK4, CDK6, CDK7, and CDK9. It is being studied for its antineoplastic activity via cell cycle arrest and induction of apoptosis in cancer cells. - **Cisplatin** is a platinum-based chemotherapy that causes DNA cross-linking and apoptosis, acting as a DNA synthesis inhibitor in rapidly dividing cells. - **Etoposide** is a topoisomerase II inhibitor that causes double-strand DNA breaks, leading to inhibition of DNA synthesis and ultimately cell death, especially active in the S and G2 phases of the cell cycle[2][5][6]. This combination is being investigated primarily in the treatment of small cell lung cancer and potentially other solid tumors, aiming to combine targeted cell cycle inhibition (roniciclib) with established DNA-damaging chemotherapies (cisplatin, etoposide).